Business Wire

FPT-CORPORATION

22.5.2024 09:21:28 CEST | Business Wire | Press release

Share
N.R. Narayana Murthy and FPT’s Truong Gia Binh Discuss Vietnam's Future and Foundations of Business Success

In an insightful dialogue themed “Accelerating Values”, Truong Gia Binh, Founder and Chairman of FPT Corporation, engaged with N.R. Narayana Murthy, Founder of Infosys, who shared his visionary outlook on Vietnam's future and the values that drive successful business leadership.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521592076/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mr. N.R. Narayana Murthy (L) and Dr. Truong Gia Binh (R) share a conversation regarding “Accelerating Values" (Photo: Business Wire)

The conversation is part of Murthy’s trip to Vietnam. The two leaders addressed a live and webcast audience of over 5,000, including tech leaders, practitioners, and young IT enthusiasts. Both highlighted their shared values and envisioned a future where respect, education, and entrepreneurial spirit accelerate growth and prosperity.

Vietnam's Bright Future

Murthy affirmed Vietnam's recent emergence as a global technology destination, reflecting the country’s commitment and investments. He also spotlighted the courage, hard work, discipline, creativity, and ambition of multiple generations of Vietnamese people. With these qualities, over the next two decades, Vietnam will become a leading developed nation in Asia and one of the fastest-growing globally.

“Vietnam's GDP is already US$4,300 per capita and will continue to grow faster than most economies in the world. I believe Vietnam will achieve prosperity for its people more quickly than many other countries in Asia,” he emphasized.

Respect: The Cornerstone of Success

The Infosys founder underscored the importance of delineating roles in the workplace, highlighting the need for clear boundaries in developing countries to ensure efficient business operations. "Respect from customers translates to profitability and attracts top talent. In my experience, money is not the most important factor — employees seek respect and appreciation for their abilities," he said.

Education and Entrepreneurship

During the conversation, Murthy also discussed the importance of entrepreneurship in driving socio-economic progress, improving lives, and the values needed to build a successful enterprise, from a long-term vision, integrity and humility, to creating favorable conditions for employees and unique values for customers.

He emphasized on the "entrepreneurial spirit", explained that entrepreneurs transform ideas into jobs, and applauded that spirit within FPT, together with the Corporation’s visionary leadership and resilience through the decades. "FPT and Vietnam have no rivals in their courage and aspirations," he affirmed.

Narayana Murthy is widely credited as one of the pioneers of Indian information technology. As India continues to command the world’s leading position in IT, a focus on modern innovations that are central to advancing global technological capabilities, is of critical importance. A 2023 report by Boston Consulting Group and NASSCOM predicts that by 2030, the Software, Automotive, and Semiconductor industries will account for over 60% of India's contributions to global ER&D (Engineering, Research & Development) sourcing. The semiconductor industry plays an especially important role, driven by global efforts to establish India as a hub for semiconductor manufacturing.

Echoing a similar sentiment, FPT Chairman, Truong Gia Binh, asserted that Vietnam’s landscape is now driven by the five areas of Artificial Intelligence, Automotive, Semiconductor, Digital Transformation, and Green Transition. These will continue to play a key role in establishing the nation’s stature in decades to come. Its growing reputation as a technology destination is evident from its thriving digital economy, with FPT as the first Vietnam-headquartered company to enter the Top 50 IT Services Companies in Asia. The Corporation also sets an ambitious target to fully integrate Vietnam into the global semiconductor ecosystem.

“Both Vietnam and India share the common goal of leveraging these sectors to establish ourselves as the key players in the global market. FPT has been doing our part in fueling these movements with our strategic investments, partnerships, development of high-value technology, as well as the emphasis on workforce training and development. We are affirmative that Vietnam can be the answer to these areas, and I am empowered by the continued confidence from an IT visionary like Murthy in FPT’s acceleration together with our country and towards our next billion-dollar milestone,” Binh said.

At the invitation of FPT Corporation, Murthy and his delegation's visit includes a series of activities, such as meeting with Vietnam's Prime Minister Pham Minh Chinh and the country's prominent companies to discuss topics critical to the continued growth of Vietnam’s digital economy, technology advancement across sectors, education, and training, as well as regional stability and development.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. During over three decades of development, FPT has constantly provided practical and effective products to millions of people and tens of thousands of business and non-business organizations worldwide, establishing Vietnam’s position on the global tech map. Keeping up with the latest market trends and emerging technologies, FPT has developed the Made-by-FPT ecosystem of services, products, solutions, and platforms, which enables sustainable growth for organizations and businesses and offers distinctive experiences to customers. In 2023, FPT recorded a total revenue of USD 2.17 billion and 48,000+ employees. For more information, please visit https://fpt.com/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521592076/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye